Evaluation of 1753 patients treated with the diagnosis of tuberculosis

Objective: In this study, we aimed to evaluate the data of 1753 patients diagnosed with tuberculosis (TB) in Süreyyapa？a Chest Diseases and Chest Surgery Training and Research Hospital for one year. Method: The study was planned as a single center retrospective. Patients diagnosed with TB were included in the study. Patient data were obtained from TB surveillance forms, bacteriology laboratory drug resistance database and octomed patient follow-up program. Results: N=1146 (65.4%) of the cases were male and n=607 (34.6%) were female. The male/female ratio was 1.8 and the highest cases were observed in the 15-24 age group in both sexes. N=1422 (81%) of all cases were pulmonary TB (PTB) (76.5% new case PTB), n=331 (18.9%) were extra pulmonary tuberculosis (EPTB) (pleural TB 86.1%, TB lymphadenitis 10.6%). Smear positivity rate was 78.7% only in patients with PTB. It was found that culture contributed 8.7% to the diagnosis. In our study, primary and secondary drug resistance was most frequently detected against H; respectively (20.2%, 34.7%). Total R primary and secondary resistance were (7.6%, 22.4%) respectively. Primary and secondary resistance for HR were (3.2%, 7%) respectively. Primary resistance to single drug was 15.4%, primary resistance to double drug was 6.0%, primary resistance to three drugs was 1.3%, and primary resistance to four drugs was 2.7%. Secondary resistance to single drug was 15.9%, secondary resistance to double drug was 10.9%, secondary resistance to three drugs was 4.3%, and secondary resistance to four was 9.9%. Primary and secondary resistance to multi-drug were found respectively (7.2%, 21.2%). 70.5% of the patients who underwent resistance test were sensitive to all drugs. Conclusions: This study is one of the largest series in a single center in our country. Smear positivity rates in patients with PTB were found to be higher than the data of our country. Drug resistance rates were found to be high due to referral of multidrug-resistant cases to our center